RxDoctor Payments Data

Murad Arif, MD

Anesthesiology · Murrieta, CANPI 1164925038

Payments from drug & device makers

$28,602in general payments, 2019–2025

Across 398 payments — averaging $71.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • Boston Scientific$5K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Nevro Corp.$1K
  • Collegium Pharmaceutical, Inc.$774
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$727
  • plus $3K from 28 others

What the payments were for

  • Consulting fees$1,2004%
  • Grants$11,25039%
  • Travel & lodging$4,52416%
  • Food & beverage$11,62741%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,602 in reported general payments places this provider in the 95th percentile of 5,717 anesthesiology providers in California.

See all anesthesiology providers in California

Medicare billing

Part B allowed, 2024
$672,109
Medicare patients
338
Services billed
6,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate17$18,310
MovantikNaloxegol Oxalate21$10,775
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen397$10,520
BelbucaBuprenorphine Hcl16$9,365
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$6,310
LinzessLinaclotide11$5,794
Lidocaine33$4,959
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen151$4,947
Buprenorphine13$4,924
Pregabalin182$3,792
Oxycodone Hcl124$2,796
Gabapentin117$1,958
Celecoxib21$1,127
Buprenorphine Hcl52$950
Naloxone Hcl16$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$122$18,31017 claims
Collegium Pharmaceutical, Inc.Belbuca$774$9,36516 claims
AbbVieLinzess$642$5,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,717 anesthesiology providers in California.

Other anesthesiology in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →